Search

Displaying results 391 - 400 of 4433 in total
  1. Drug

    Alfuzosin

    go.drugbank.com/drugs/DB00346
    Approved

    [L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.

    Products: UROXATRAL 10MG, ALFUZOSIN ABZ 10MG
  2. Drug

    Netilmicin

    go.drugbank.com/drugs/DB00955
    Approved

    Netilmicin is a semisynthetic 1-N-ethyl derivative of sisomycin, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity. … Netilmicin inhibits protein synthesis in susceptible organisms by binding to the bacterial 30S ribosomal subunit and interfering with mRNA binding and the acceptor tRNA site.

    Products: LOTIFAR 50MG/ML INJECTION, Netromycin Inj 50mg/ml
  3. Drug

    Chlorthalidone

    go.drugbank.com/drugs/DB00310
    ApprovedInvestigational

    Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. … Chlorthalidone improves blood pressure and swelling by preventing water absorption from the kidneys through inhibition of the Na+/Cl− symporter in the distal convoluted tubule cells in the kidney.

    Mixtures: EDARBI CLD® 40MG/12.5MG, ATENOCOMP 1A 50MG/12.5MGProducts: Hygroton 50mg, Uridon Tab 50mg
  4. Drug

    Guanethidine

    go.drugbank.com/drugs/DB01170
    ApprovedWithdrawn

    An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. … It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.

    Products: Guanethidine 10 Tab 10mg, Apo Guanethidine Sulfate Tab 10mg
  5. Drug

    Topotecan

    go.drugbank.com/drugs/DB01030
    ApprovedInvestigational

    It works by inhibiting DNA topoisomerases, type I.

    Products: Hycamtin Injection 1mg, HYCAMTIN INJECTION 4MG
  6. Drug

    Calcium lactate

    go.drugbank.com/drugs/DB13231
    ApprovedVet approved

    It is prepared commercially by the neutralization of lactic acid with calcium carbonate or calcium hydroxide. … Approved by the FDA as a direct food substance affirmed as generally recognized as safe, calcium lactate is used as a firming agent, flavoring agent, leavening agent, stabilizer, and thickener [L2741].

    Products: PRI-CALCIUM TABLETS 300MG, Calact Tablet 300mg
  7. Drug

    Nitroglycerin

    go.drugbank.com/drugs/DB00727
    ApprovedInvestigational

    Nitroglycerin, also known as glyceryl trinitrate, is an organic nitrate and a vasodilating agent that was first discovered in 1847. Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced ...

    Products: NITRODERM TTS 10 (10MG/24HR), Nitro-dur 0.3 - 60mg/15 Sq Cm, 0.3mg/hr
  8. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with

    Products: SAPHRIS SUBLINGUAL TABLET 10MG, SYCREST 10MG DILALTI TABLET, 100 TABLET
  9. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to … Lemborexant is a novel dual orexin receptor antagonist used in the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

    Products: DAYVIGO FILM-COATED TABLET 10MG, Dayvigo 10mg Film coated tablet
  10. Drug

    Enfortumab vedotin

    go.drugbank.com/drugs/DB13007
    ApprovedInvestigational

    [L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000] … [L10836] It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable

    Products: Padcev 30mg Powder for Concentrate for Solution for Infusion, Padcev 20mg Powder for Concentrate for Solution for Infusion